Type of parameterParameterBRCA1 rangeHigh risk rangeRaised risk range
ProbabilitiesMortality of false negatives5 145 – 5 41317 926 – 20 33139 093 – 45 444
Prognosis (1) BRCA14 342 – 6 629N/AN/A
Prognosis (2) BRCA14 735 – 5 872N/AN/A
Prognosis (3) BRCA14 015 – 7 843N/AN/A
Prognosis (1) non- BRCA1N/A13 530 – 30 76628 510 – 74 551
Prognosis (2) non- BRCA1N/A15 535 – 23 67733 325 – 54 123
Prognosis (3) non- BRCA1N/A11 940 – 46 40425 050 – 118 222
CostsMRI scan4 413 – 6 57815 757 – 23 57834 804 – 51 657
USS5 168 – 5 31218 485 – 19 00640 683 – 41 805
Mammography5 189 – 5 46418 557 – 19 56340 835 – 43 016
UtilitiesIn treatment5 212 – 5 26918 661 – 18 83241 205 – 41 283
False negatives4 973 – 5 53817 270 – 20 49737 918 – 45 210
Screening effect on incidenceIncrease in annual incidence due to mammography5 010 – 5 48217 932 – 19 62239 379 – 43 284

From: Appendix 6, Univariate Sensitivity Analysis Strategy and Detailed Results

Cover of Familial Breast Cancer
Familial Breast Cancer: The Classification and Care of Women at Risk of Familial Breast Cancer in Primary, Secondary and Tertiary Care: Update [Internet].
NICE Clinical Guidelines, No. 41.
National Collaborating Centre for Primary Care (UK).
Copyright © 2006, National Collaborating Centre for Primary Care.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.